Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
Department
Adjust height of sidebar
KMap
Department
Cancer Center Division
76 active people
99 grants
Recent Grants
A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 BiSpecific Antibody, Versus Investigator's Choice in Previously Untreated
2024
·
$7.5M
immunotherapy,
cancer treatment,
clinical trials,
biopharmaceuticals,
lymphoma
A Phase 1/2 Open-Label, Umbrella Platform Design of lnvestigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Gastroesophageal Cancer: Master (KE
2024
·
$4.5M
cancer,
immunotherapy,
clinical trial,
chemotherapy,
treatment
A Phase 3, Randomized, Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed O
2024
·
$2.2M
prostate cancer,
clinical trials,
metastatic cancer,
treatment comparison,
hormone therapy
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 As Single-Agent And Combination Therapy In Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
2024
·
$1.6M
pharmacokinetics,
cancer,
drug therapy,
safety,
dose escalation
A Phase 3 Randomized Clinical Study of MK-4280A (coformulated favezelimab (MK-4280) plus pembrolizumab (MK-3475)) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory C
2024
·
$1.3M
immunotherapy,
clinical trial,
cancer treatment,
precision medicine
A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphom
2024
·
$1.2M
lymphoma,
efficacy,
safety,
treatment,
clinical trial
Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the Treatment of Selected HER2-Mutated or Overexpres
2024
·
$769.7K
clinical trial,
cancer treatment,
drug efficacy,
safety evaluation
A Phase 1b/2 Open-Label Study of Disitamab Vedotin Monotherapy or in Combination with Other Anti-Cancer Therapies in Solid Tumors
2024
·
$724K
cancer,
immunotherapy,
monotherapy,
clinical trial,
solid tumors
A Phase 1b/2a, Double-Blind, Placebo-Controlled, Three Arm, Randomized Study Evaluating Continuous Infusion of LSTA1 Over 4 Hours When Added to Standard of Care (SoC) Versus a Single Intravenous (IV)
2024
·
$635.9K
clinical trials,
drug therapy,
pharmacology,
medical research,
therapeutic interventions
A Phase 1 Study With ABBV-CLS-484 Alone And In Combination In Subjects With Locally Advanced or Metastatic Tumors
2024
·
$635K
oncology,
clinical trial,
pharmacology
A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREG) in Patients with Locally Advanced (Inoperable) or Metastatic Renal Cell Carcinoma
2024
·
$625.4K
clinical trial,
oncology,
combination therapy,
renal cell carcinoma,
safety and tolerability
Phase 1 Trial Evaluating the Safety and Tolerability of Gamma Delta T-Cell Infusions in Combination with Low Dose Radiotherapy in Subjects with Stage 4 Metastatic Non-Small Cell Lung Cancer
2024
·
$577.4K
immunotherapy,
radiotherapy,
lung cancer,
clinical trial,
metastatic cancer
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant Vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for
2024
·
$559.6K
breast cancer,
adjuvant therapy,
immunotherapy,
clinical trial,
hormone receptor
A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Tre
2024
·
$548.6K
oncology,
clinical trials,
chemotherapy,
cancer treatment,
drug combination
A Phase 3 Randomized, Open-label Study Of Op-1250 Monotherapy Vs Standard Of Care For The Treatment Of Er+, Her2- Advanced Or Metastatic Breast Cancer Following Endocrine And Cdk 4/6 Inhibitor Therapy
2024
·
$512.6K
monotherapy,
endocrine therapy,
metastatic breast cancer
Brightline-4: A Phase III Open-label, Single-arm, Multi-center Study to Assess the Safety and Efficacy of Brigimadlin (BI 907828) Treatment in Patients With Treatment -na?ve or Pre-treated Advanced D
2024
·
$503K
pharmacology,
clinical trials,
oncology,
drug safety,
medical research
A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator's Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/
2024
·
$434.6K
clinical trials,
cancer treatment,
drug efficacy,
therapeutic intervention,
precision medicine
A Phase 1/2 Open-Label, Multicenter, Global Trial to Characterize the Safety, Tolerability and Preliminary Efficacy of CFT1946 as a Monotherapy and in Combination with Trametinib in Subjects with BRAF
2024
·
$433.9K
clinical trials,
oncology,
drug safety,
precision medicine,
combination therapy
Development of a Molecular Assay to Diagnose Malignant Pleural Effusions
2024
·
$404.1K
molecular diagnostics,
cancer diagnosis,
pleural effusions,
medical testing
A Phase Ib/III, Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Fact
2024
·
$352.6K
cancer treatment,
combination therapy,
clinical trial,
cell signaling
People
Ann Bridges
Conference and Events Planner II
AJ Steuer
Research Compliance Administrator I
Aradhana Kari
Research Compliance Administrator II
Alaina Krone
Clinical Research Manager III
Amy Carrier
Research Nurse III
Angelique Thornton
Research Nurse II
Angelica Erunez
Research Compliance Administrator II
Amy Selegue
Clinical Research Manager II
Autumn Lester
Research Technician II
Angela Yung
Researcher/Scientist III
Bryan Clines
Research Compliance Administrator III
Beth Estevez Quintana
Clinical Research Coordinator II
Betsey Wagener
Research Program Administration Manager IV
Betsy Wertheim
Biostatistician II
Brianna Loughran
Clinical Research Coordinator II
Brianna Denton
Research Compliance Manager I
Bethany Skovan
Research Specialist, Senior
Claudia Al Khairi
Clinical Research Coordinator II
Catherine Cordova
Research Professional I
Michele Chu-Pilli
Research Program Administration Officer III
Carolyn Lane
Research Laboratory Manager I
Carole Kepler
Laboratory Coordinator II
Carol Carpenter
Research Development Professional IV
Cyndie Neal
Clinical Research Coordinator II
Daniel Buster
Researcher/Scientist IV
Dakota Hartliep
Research Technician III
Diana Dawson
Research Compliance Administrator II
Claudia Espitia
Researcher/Scientist IV
Francois Chu
Research Compliance Administrator I
Lupita Ramos-Barrera
Clinical Research Manager I
Gillian Paine-Murrieta
Research Laboratory Manager III
Haiyan Cui
Research Specialist, Senior
Jaime Gard
Laboratory Coordinator III
Jose Guillen-R
Biostatistician II
Kai Kau
Clinical Research Coordinator II
Kathleen Molinar
Research Program Administration Officer II
Carmen Arredondo
Administrative Support Assistant I
Laura Duckett
Clinical Research Coordinator III
Lizeth Evangelista
Research Compliance Administrator II
Lora Inclan
Clinical Research Coordinator III
Linda Maynard
Research Program Administration Officer I
Elizabeth McPeak
Clinical Research Manager IV
Liliana Mendivil
Community Outreach Professional II
Maga Sanchez
Research Laboratory Manager I
Namoonga Mantina
Community Outreach Manager I
Marco Padilla-Rodriguez
Researcher/Scientist IV
Mark Febbo
Communications Manager III
Michelle Perez-coronado
Community Outreach Professional I
Mitzi Miranda
Research Program Administration Officer III
Michael Yozwiak
Researcher/Scientist III
Melissa Molina
Research Compliance Administrator II
Michele Holland
Research Compliance Administrator II
Maria Prevatt
Research Program Administration Officer IV
Monica Yellowhair
Community Outreach Manager II
Niyuri Fleming
Research Compliance Administrator III
Assumpta Nsengiyunva
Laboratory Coordinator I
Octavio Castanos
Research Compliance Administrator II
Camilo Ortiz
Community Outreach Professional I
Prisca Zimmerman
Project Manager III
Patricia Robles Quihuis
Research Nurse III
Ruth Ca?amar
Research Program Administration Officer III
Rosa Fung
Financial Analysis Manager IV
Debora Aguirre
Administrative Support Assistant III
Sylvia DeCero
Research Nurse III
Sophia Farrisi
Laboratory Coordinator I
Jaron Solsky
Clinical Research Manager I
Sandra Ortega
Clinical Research Coordinator II
Stephanie Soto
Clinical Research Coordinator III
Sonja Velickovic
Laboratory Coordinator I
Sylvia Paton
Clinical Research Manager III
Teri Bankhead
Administrative Operations Manager V
Tiffanie Cagle
Clinical Research Coordinator II
Thomas Schlabach
Clinical Research Coordinator II
Terri Katz
Research Compliance Administrator I
Victoria Valdez Ruiz
Clinical Research Coordinator II
Wade Chew
Research Technologist III
Funding support
7 funding agencies since 2021
Research expenses history
